Conference
Rivaroxaban - An Oral, Direct Factor Xa Inhibitor - for Thromboprophylaxis after Total Knee Arthoplasty: The RECORD3 Trial.
Abstract
Abstract
Introduction Rivaroxaban is a novel, oral, direct Factor Xa inhibitor in advanced clinical development for the prevention and treatment of thromboembolic disorders. In RECORD3, a phase III trial, the efficacy and safety of once-daily (od) rivaroxaban was compared with od enoxaparin for the prevention of venous thromboembolism (VTE) in patients undergoing total knee arthroplasty (TKA).
Authors
Lassen MR; Turpie AGG; Rosencher N; Borris LC; Ageno W; Lieberman JR; Bandel TJ; Misselwitz F
Volume
110
Publisher
American Society of Hematology
Publication Date
November 16, 2007
DOI
10.1182/blood.v110.11.308.308
Conference proceedings
Blood
Issue
11
ISSN
0006-4971